Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

SPK-8011
Read More
Spark Therapeutics’ SPK-8011 is an adeno-associated virus-mediated gene therapy, aiming to restore normal clotting function to patients with hemophilia A.
May 4, 2018
Find out more
Latuda
Read More
Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.
March 29, 2019
Find out more
Napabucasin
Read More
Napabucasin (Dainippon Sumitomo) is designed to selectively and simultaneously inhibit multiple key pathways associated with tumor growth and development by targeting the STAT3 transcription factor.
December 11, 2017
Find out more
MPC-150-IM
Read More
MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs).
December 11, 2017
Find out more
Inbrija
Read More
Inbrija (Acorda Therapeutics) is an inhaled formulation of levodopa, in development as an adjunct to existing oral levodopa formulations in patients experiencing motor fluctuations.
June 21, 2018
Find out more
Vraylar
Read More
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.
March 29, 2018
Find out more
Dacomitinib
Read More
Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including…
August 30, 2018
Find out more
Cyramza
Read More
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.
September 9, 2019
Find out more
Neratinib
Read More
Neratinib (Puma Biotechnology) is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptor (HER)1, HER2, HER4, and epidermal growth factor receptor kinases.
March 9, 2015
Find out more
Live-attenuated RSV vaccines
Read More
In collaboration with the National Institute of Allergy and Infectious Diseases, AstraZeneca is developing a portfolio of three live-attenuated vaccines for the prevention of serious lower respiratory tract infections.
October 5, 2018
Find out more
Prezista franchise
Read More
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.
June 28, 2019
Find out more
Farydak
Read More
Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor. Inhibition of HDAC leads to relaxed chromatin and increased transcription.
August 9, 2018
Find out more
esuberaprost
Read More
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
Jardiance
Read More
Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor originally developed by Boehringer Ingelheim for the treatment of type 2 diabetes.
February 27, 2019
Find out more
Cosentyx
Read More
Cosentyx (secukinumab; Novartis) is a fully human monoclonal antibody which acts by neutralizing interleukin (IL)-17A. IL-17A is a pro-inflammatory cytokine secreted by activated T cells. It is indicated for the treatment of plaque psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis.
May 16, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *